Shield Therapeutics plc reported record sales for ACCRUFeR and achieved positive cash flow in 2025 [1].
This financial shift suggests the company is moving toward sustainable profitability. The transition comes as the firm scales its operations in the U.S. market, reducing its reliance on external funding for daily operations.
During a Q2 2026 sales and trading call, the company detailed its performance from the previous year [1]. The growth was primarily driven by a 56% increase [2] in U.S. ACCRUFeR net revenue. This surge brought the net revenue for the product to approximately $46 million [2].
Shield Therapeutics said 2025 was its strongest year to date [1]. The company has also made leadership changes to manage this growth, including the appointment of Michael Jensen as chief financial officer [3].
ACCRUFeR is the company's primary commercial driver in the United States. The increase in revenue reflects broader adoption of the treatment and a more efficient commercial strategy. By turning cash flow positive in 2025, the firm has established a financial cushion to support further development, and market expansion.
The company's recent reporting emphasizes a pivot from a research-heavy phase to a commercial-growth phase. The 56% revenue jump [2] indicates that the product is gaining traction with healthcare providers and patients in the U.S. market.
“Shield Therapeutics reported its strongest year to date in 2025”
The transition to positive cash flow marks a critical inflection point for Shield Therapeutics. For biotechnology and pharmaceutical firms, moving from a 'burn rate' to a self-sustaining financial model reduces the risk of dilutive equity raises and provides the capital necessary to fund future pipeline projects without relying solely on investors.
